Litigation of unlicensed US stem cell products.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40315833.
- Also identified by DOI 10.1016/j.stem.2025.04.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Financial dispositions against unapproved stem cell interventions have grown significantly, with successful class-action lawsuits, malpractice claims, and collaborative prosecutions between government agencies. In addition to improved dispositions, federal circuit courts have given unanimous affirmation to the FDA's regulatory authority over stem cell interventions, establishing critical precedents for oversight.
Medical subject headings
- Stem Cells
- Stem Cell Transplantation